Tag: liraglutide market insights

Uncover key drivers, emerging technologies, and competitive movements shaping the throat lozenges market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Throat Lozenges Market Size?

The liraglutide market has shown substantial growth in recent years. It is anticipated to expand from $6.38 billion in 2024 to $6.88 billion in 2025, progressing at a compound annual growth rate (CAGR) of 7.9%. This past expansion can be ascribed to several factors, including the rising number of individuals diagnosed with type 2 diabetes, increasing rates of obesity, extensive clinical trials, heightened awareness concerning diabetes complications, and advancements in drug delivery systems.

The liraglutide market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $9.45 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.3%. This expansion during the projection period stems from factors such as the rise in insurance and reimbursement frameworks, advancements in healthcare infrastructure, heightened awareness and educational efforts, an expanding elderly demographic, and the increasing incidence of diabetes. Key developments anticipated in this period encompass the application of artificial intelligence and machine learning, a rising need for wearable technologies, the incorporation of continuous glucose monitoring, breakthroughs in biotechnology, and the creation of digital health platforms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

What Core Market Drivers Are Expanding The Throat Lozenges Industry?

The expanding number of individuals with diabetes is anticipated to boost the growth of the liraglutide market in the future. Diabetes is a long-term illness characterized by the body’s inability to adequately control blood sugar levels, stemming from either inadequate insulin production or inefficient utilization of insulin. The occurrence of diabetes is on the rise, influenced by factors like inactive lifestyles, poor dietary habits, and increasing global obesity levels. Medications for diabetes, including liraglutide, function by imitating the effects of the GLP-1 hormone, thereby improving insulin secretion, reducing blood glucose, and encouraging weight loss, which assists in managing type 2 diabetes. For example, in March 2024, a report from the Government of the United Kingdom, a UK-based information source, indicated that in March 2023, the percentage of individuals with type 1 diabetes in England who received all eight recommended care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in the previous year. Consequently, the growing population affected by diabetes is fueling the expansion of the liraglutide market.

What Segment Insights Are Highlighted In The Throat Lozenges Market Report?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Which Notable Trends Are Transforming The Throat Lozenges Market Outlook?

Leading companies in the liraglutide market are actively developing new products, such as generic GLP-1, aiming to expand treatment options and fulfill the market’s need for more cost-effective alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists manufactured after the patent protection on the original branded medications has expired, providing economical choices for managing conditions like type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, introduced the first generic GLP-1, similar to Victoza, in the U.S. market, thereby addressing the growing demand for these therapies. Liraglutide injections are prescribed to enhance blood sugar management in adults and children aged 10 and above with type 2 diabetes and to reduce the risk of cardiovascular incidents in adults who have type 2 diabetes and existing cardiovascular conditions.

Which Firms Are Driving Innovation Within The Throat Lozenges Market?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

What Regional Trends Are Shaping Growth In The Throat Lozenges Market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

Browse Through More Reports Similar to the Global Throat Lozenges Market 2025, By The Business Research Company

Antidiarrheals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

Anti Aging Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Anticoagulant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Liraglutide Market Today And What Is Its Future Size?

The market size for liraglutide has seen significant growth in the past few years. The market value is expected to rise from $6.38 billion in 2024 to $6.88 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The growth during the historical period can be linked to an increase in the diagnosis of type 2 diabetes, an escalation in obesity rates, numerous clinical trials, heightened awareness of complications related to diabetes, and ongoing advancements in drug delivery systems.

The market for liraglutide is foreseen to experience robust growth in the coming years, anticipated to rise to a value of “$9.45 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.3%. The prediction for this growth is primarily due to factors such as expanding insurance coverage and reimbursement practices, development in healthcare facilities, rising awareness and educational campaigns, increasing elderly population, and the growing occurrences of diabetes. Key trends noted for the forecast period encompasses the application of artificial intelligence and machine learning, the surge in demand for wearable technology, integration with continuous glucose monitoring, advancements in biotechnology, and the evolution of digital health platforms.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

Which Key Factors Are Fueling Growth In The Liraglutide Market?

The rise in the number of individuals with diabetes is anticipated to spur the expansion of the liraglutide market. Diabetes is a persistent disorder characterized by the body’s inability to correctly maintain blood sugar levels, this can be a result of an insufficient production of insulin or ineffective use of the insulin. Escalating rates of diabetes are attributed to factors such as inactive lifestyles, unhealthy eating habits, and the global emergence of obesity. Medications for diabetes like liraglutide are effective as they emulate the performance of the hormone GLP-1, which bolsters insulin secretion, reduces blood sugar levels, and stimulates weight loss, subsequently assisting in the control of type 2 diabetes. For example, as per a March 2024 report by the Government of the United Kingdom, a UK-based information website revealed that in March 2023, the percentage of individuals with type 1 diabetes in England receiving all 8 care processes at GP practices participating in the NDA rose to 43.8% from 35.2% the previous year. Therefore, the growing diabetic population serves as a driving factor for the liraglutide market’s expansion.

What Segmentation Insights Are Provided In The Liraglutide Market Research?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Which Notable Trends Are Transforming The Liraglutide Market Outlook?

Leading firms in the liraglutide market are focusing on the creation of innovative products such as generic GLP-1, aiming to increase the range of treatments available and cater to the need for cost-effective options. When patents for the original branded medications expire, generic GLP-1, which are versions of GLP-1 receptor agonists, are created, offering more affordable alternatives for managing conditions like type 2 diabetes and obesity. For example, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1, comparable to Victoza, in the U.S. market in June 2024, thereby fulfilling the growing demand for such treatments. Adults and children aged 10 years and older with type 2 diabetes are recommended liraglutide injections for better blood sugar control and to decrease the probability of cardiovascular events in adults with type 2 diabetes and existing cardiovascular diseases.

Which Firms Are Driving Innovation Within The Liraglutide Market?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Liraglutide Market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Throat Lozenges Market Evolve in Terms of Growth and Size by 2029?

The market size of liraglutide has seen robust growth in the past few years. The market is expected to expand from $6.38 billion in 2024 to a value of $6.88 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.9%. Factors such as a rising prevalence of type 2 diabetes, increasing obesity rates, extensive clinical research, heightened awareness of the complications associated with diabetes, and advancements in drug delivery systems have all contributed to the growth experienced during the historic period.

In the coming years, the liraglutide market size is projected to witness remarkable growth. The market is anticipated to surge to “$9.45 billion in 2029 with a compound annual growth rate (CAGR) of 8.3%. Various reasons contributing to this growth in the anticipated period include the enhancement of insurance and reimbursement policies, development of medical infrastructure, raised awareness and educational measures, an increase in the aging population, and a high incidence rate of diabetes. Key trends for the forecast period encompass the integration of artificial intelligence and machine learning, an increasing affinity for wearable technology, incorporation of continuous glucose monitoring, advancements in biotechnology and the emergence of digital health platforms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

What factors are expected to fuel Throat Lozenges market growth in the coming years?

The throat lozenges market is projected to grow due to the escalating occurrence of respiratory ailments. These diseases typically affect the lungs and other components of the respiratory system. Throat lozenges play a key role in alleviating and treating infections and diseases within the respiratory tract. As an example, the Forum of International Respiratory Societies (FIRS), a US-based advocate for respiratory health, reported in September 2022 that around 200 million people worldwide suffer from chronic obstructive pulmonary disease, or COPD. This disease contributes to roughly 3.2 million deaths every year. Therefore, this rise in respiratory ailments is set to fuel the growth of the throat lozenges market.

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Which Trends Are Redefining The Future Landscape Of The Throat Lozenges Industry?

In the liraglutide market, leading firms are diversifying their product offerings through the innovation of products such as generic GLP-1, catering to the growing need for cost-effective alternatives. Generic GLP-1 denotes GLP-1 receptor agonists produced once the original brand medications’ patent protection has expired, providing an economical option for managing conditions like obesity and type 2 diabetes. For example, Teva Pharmaceutical Industries Ltd, a pharmaceutical corporation based in Israel, launched the inaugural generic GLP-1, a product mirroring Victoza, into the U.S. market in June 2024. This move responded to the escalating demand for such treatments. Liraglutide injections are recommended for improving blood glucose control in children aged 10 and above as well as adults diagnosed with type 2 diabetes and in reducing cardiovascular event risks in adults suffering from type 2 diabetes along with pre-existing cardiovascular diseases.

What Are The Most Active Companies In The Throat Lozenges Market Today?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Which Regional Markets Are Attracting The Most Investment In Throat Lozenges?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Liraglutide Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the liraglutide market has seen a robust growth. Projections indicate an increase in market size from $6.38 billion in 2024 to $6.95 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. The growth witnessed in the historic period is largely due to the surge in type 2 diabetes diagnoses, escalating obesity levels, widespread clinical trials, enhanced understanding of diabetes-related complications, and innovative advancements in drug delivery systems.

What Is the Forecast for the Liraglutide Market Size Through 2029?

In the coming years, robust growth is anticipated in the liraglutide market. The market is predicted to expand to $9.66 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This projected growth can be linked to a rise in insurance and reimbursement policies, development in healthcare infrastructure, increased awareness and educational initiatives, an aging population, and the escalating incidence of diabetes. Dominant trends for the forecast period include artificial intelligence and machine learning applications, a heightened demand for wearable technology, the integration of continuous glucose monitoring, advancements in biotechnology, and the emergence of digital health platforms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

What are the Key Market Players in Liraglutide Market and How They’re Evolving?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

What Are the Primary Growth Drivers in the Liraglutide Market?

The surge in the population suffering from diabetes is predicted to fuel the expansion of the liraglutide market. Diabetes is a persisting ailment in which the body struggles to control blood sugar levels adequately, either due to insufficient insulin production or ineffective usage of insulin. The prevalence of diabetes is on the rise due to factors like inactive lifestyles, unhealthy eating habits, and escalating obesity rates globally. Diabetes medications like liraglutide assist by imitating the function of the hormone GLP-1, which boosts insulin secretion, reduces blood sugar levels, and encourages weight loss, consequently helping in the management of type 2 diabetes. For example, in March 2024, a report by the UK Government, stated that the ratio of people with type 1 diabetes in England who received all 8 care processes at GP practices participating in the NDA rose to 43.8%, a significant increase from 35.2% in the previous year. Thus, the growing diabetic population is augmenting the growth of the liraglutide market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

What Are the Leading Segments in the Global Liraglutide Industry?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

What Are the Key Market Trends in the Liraglutide Industry?

Leading entities in the liraglutide market are exploring the new product development stream, emphasizing on the creation of products like the generic version of GLP-1. These moves are geared towards broadening patient treatment avenues while satisfying the market’s call for more economically viable options. Generic GLP-1 points to variants of GLP-1 receptor agonists that come into production after the patents for the original branded substances expire, presenting cost-effective substitutes to treat health problems such as type 2 diabetes and obesity. To illustrate, Teva Pharmaceutical Industries Ltd., a notable pharmaceutical firm hailing from Israel, launched the first generic GLP-1, comparable to Victoza, in the US market in June 2024, answering the growing demand for such treatments. In the context of managing blood sugar levels in adults and individuals aged over 10 suffering from type 2 diabetes, as well as in decreasing the danger of cardiovascular incidents in adults having both type 2 diabetes and existing cardiovascular diseases, liraglutide injections are prescribed.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

What Is the Regional Outlook for the Liraglutide Market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

This Report Delivers Insight On:

1. How big is the liraglutide market, and how is it changing globally?

2. Who are the major companies in the liraglutide market, and how are they performing?

3. What are the key opportunities and risks in the liraglutide market right now?

4. Which products or customer segments are growing the most in the liraglutide market?

5. What factors are helping or slowing down the growth of the liraglutide market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Liraglutide Market?

The upsurge in the number of diabetic individuals is anticipated to boost the liraglutide market’s progression. Diabetes, a chronic ailment, impairs the body’s capacity to regulate blood sugar levels because of insufficient insulin generation or ineffective insulin usage. Factors like inactive lifestyles, unhealthy food habits, and escalating obesity rates globally contribute to the rising incidence of diabetes. Diabetes medications like liraglutide function by imitating the GLP-1 hormone’s effect, improving insulin secretion, reducing blood sugar levels, and fostering weight loss, thus aiding the control of type 2 diabetes. For instance, a report by the UK government in March 2024 cited that the percentage of type 1 diabetic individuals in England undergoing all eight care processes at GP practices participating in the NDA had surged to 43.8% in March 2023, compared to 35.2% the preceding year. Hence, the mounting diabetic population is fuelling the growth of the liraglutide market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

#How Does the ProjectedLiraglutide Market Growth Compare Over the Forecast Period?

In the past few years, the liraglutide market has experienced significant growth. The market size is projected to increase from $6.38 billion in 2024 to $6.95 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period is credited to factors such as rising instances of type 2 diabetes diagnoses, escalating obesity rates, comprehensive clinical trials, increasing awareness about complications from diabetes, as well as innovations in the delivery systems of drugs.

The market size of liraglutide is predicted to experience significant expansion in the coming years, reaching an estimated value of $9.66 billion in 2029, with a compound annual growth rate (CAGR) of 8.6%. This projected growth in the forecasted period can be credited to several factors such as the rise in insurance and reimbursement policies, development of healthcare infrastructures, enhanced awareness and educational programs, an increasing aging population, and the growing occurrence of diabetes. Key trends within this period of growth are expected to involve the application of artificial intelligence and machine learning, the growing demand for wearable technology, the integration of continuous glucose monitoring, progress in biotechnology, and the evolution of digital health platforms.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

What Are the Most Significant Market Trends Transforming theLiraglutide Market?

Leading firms in the liraglutide market are innovating new products like generic GLP-1 with the aim to broaden treatment choices and fulfill market need for more cost-effective substitutes. Generic GLP-1 is an after-patent production of the original patented medication, providing a cheaper alternative for the treatment of type 2 diabetes and obesity. In June 2024, for example, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1, mirroring Victoza, to cater to the increasing demand for such treatments in the U.S. market. Doctors recommend Liraglutide injections to improve blood sugar regulation in adults and children aged 10 and above who have type 2 diabetes and to reduce the threat of cardiac events in adults with type 2 diabetes who also have cardiovascular diseases.

What Are the Top Market Players Propelling the Growth of theLiraglutide Industry?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Which Primary Segments of the Liraglutide Market Are Driving Growth and Industry Transformations?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Liraglutide Market?# Market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Liraglutide Market 2025, By The Business Research Company:

Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Anti-Aging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Antidiarrheals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the liraglutide market grown in recent years?

In the past few years, there has been a significant increase in the size of the liraglutide market. Predictions indicate that it will expand from $6.38 billion in 2024 to $6.95 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. Factors catalyzing this growth during the historic period include an uptick in the diagnosis of type 2 diabetes, ballooning obesity rates, widespread clinical trials, heightened awareness of the implications of diabetes, and the emergence of innovative drug delivery systems.

How is the liraglutide market size expected to evolve during the forecast period?

In the coming years, the liraglutide market is set to witness robust expansion, escalating to $9.66 billion by 2029, with an 8.6% compound annual growth rate (CAGR). Factors contributing to this positive projection during the forecast period range from enhanced insurance coverage and reimbursement methodologies, improvements in the healthcare infrastructure, increased knowledge and educational strategies, the rise in the older demographics, and a heightened occurrence of diabetes. Future trends within this period are expected to encompass the incorporation of artificial intelligence and machine learning, the growing demand for wearable technology, the integration of continuous glucose monitoring, progress in biotechnology, and the creation of digital health platforms.

Get your liraglutide market report here!

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Which key drivers are propelling the liraglutide market’s growth?

The growth of the liraglutide market is anticipated to be fueled by the rising diabetic population. Diabetes, a long-term disorder wherein the body struggles to regulate blood sugar levels due to insufficient insulin production or ineffective insulin utilization, is seeing an upward trend. This increase in diabetes is attributed to factors such as inactive lifestyles, unhealthy food habits, and a global surge in obesity. Liraglutide, a diabetes medication, aids by replicating the effect of the GLP-1 hormone, increasing insulin release, reducing blood sugar, and supporting weight loss, thus aiding to control type 2 diabetes. For example, as per a report from the UK Government, a domestic information website, in March 2023, the percentage of individuals with type 1 diabetes in England that received all the eight-care processes from GP practices participating in the NDA rose to 43.8%, an increase from 35.2% the previous year. Therefore, the burgeoning diabetic population is contributing to the expansion of the liraglutide market.

What are the market segments in the liraglutide industry?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies

3) By Type Of Application: Diabetes Treatment, Weight Management

4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:

1) By Victoza: Type 2 Diabetes Treatment Or Weight Management

2) By Saxenda: Weight Loss Treatment Or Obesity Management

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

Which leading companies are shaping the growth of the liraglutide market?

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Which trends are expected to transform the liraglutide market?

Leading enterprises in the liraglutide market are focusing on creating innovative products like the generic GLP-1, with the intent to broaden the available treatment alternatives and cater to the market’s need for cost-effective options. Generic GLP-1 translates to variants of GLP-1 receptor agonists, which are developed post the patent protection expiry of the original branded medicines, providing affordable alternatives to manage conditions such as type 2 diabetes and obesity. To give an example, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm, launched the first generic GLP-1, akin to Victoza, in the U.S market in June 2024 to satisfy the growing need for these treatments. Liraglutide injections are recommended to improve blood sugar control in adults and children over the age of 10 who have type 2 diabetes and to mitigate the incidence of heart-related events in adults suffering from type 2 diabetes and pre-existing cardiovascular diseases.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

Which geographic areas are influencing the growth of the liraglutide market?

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Anti-Aging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Antidiarrheals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Expansion Rate of the Liraglutide Market in the 2024-2033 Forecast?

The liraglutide market size has grown strongly in recent years. It will grow from $5.87 billion in 2023 to $6.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to the increasing number of people diagnosed with type 2 diabetes, growing obesity rates, extensive clinical trials, growing awareness of diabetes complications, and rising innovations in drug delivery systems.

The liraglutide market is projected to see substantial growth, expected to reach $8.90 billion by 2028 at a CAGR of 8.7%. Factors contributing to this growth include enhanced insurance and reimbursement policies, healthcare infrastructure development, increasing awareness and educational initiatives, a growing aging population, and the rising prevalence of diabetes. Key trends include the use of AI and machine learning, demand for wearable technology, continuous glucose monitoring integration, advancements in biotechnology, and the development of digital health platforms.

What Factors Are Catalyzing the Growth of the Liraglutide Market?

The rising diabetic population is expected to drive the growth of the liraglutide market. With diabetes on the rise due to unhealthy lifestyles, drugs like liraglutide, which help regulate blood sugar levels and promote weight loss, are becoming essential for managing type 2 diabetes.

Claim Your Free Sample of the Global Liraglutide Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

Which Segments Are Important in the Liraglutide Market Landscape?

The liraglutide market covered in this report is segmented –

1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings

What Are the Groundbreaking Trends in the Liraglutide Market?

Major companies in the liraglutide market are introducing novel products, such as generic GLP-1, to meet the growing demand for affordable alternatives. Generic GLP-1 provides cost-effective treatment options for conditions like type 2 diabetes and obesity.

Order Now for Fast Delivery of Your Liraglutide Market Report!

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

What Are the Key Regions Powering Growth in the Liraglutide Market?

North America was the largest region in the liraglutide market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Liraglutide Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the liraglutide market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Liraglutide Market Include

1. Liraglutide Market Executive Summary
2. Liraglutide Market Segments
3. Liraglutide Market Size And Template Market Growth Rate
4.  Key Liraglutide Market Trends
5. Major Liraglutide Market Drivers
……
25. Key Mergers And Acquisitions In The Liraglutide Market
26. Top Liraglutide Companies
27. Liraglutide Market Opportunities And Strategies
28. Liraglutide Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:

Antidiarrheals Market 2024

https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

Anti-Aging Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Television Network Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/television-network-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The liraglutide market size has grown strongly in recent years, increasing from $5.87 billion in 2023 to $6.38 billion in 2024, at a compound annual growth rate (CAGR) of 8.6%. This growth in the historic period can be attributed to factors such as the rising number of people diagnosed with type 2 diabetes, escalating obesity rates, extensive clinical trials, growing awareness of diabetes complications, and innovative advancements in drug delivery systems. The liraglutide market size is projected to continue its robust growth, expected to reach $8.90 billion in 2028, with a CAGR of 8.7%. This anticipated growth is driven by factors like improving insurance and reimbursement policies, developing healthcare infrastructure, increasing awareness through educational initiatives, a growing aging population, and the rising prevalence of diabetes. Major trends expected to shape the forecast period include the incorporation of artificial intelligence and machine learning, heightened demand for wearable technology, integration of continuous glucose monitoring, advancements in biotechnology, and the evolution of digital health platforms.

The increasing population of individuals with diabetes is likely to propel the growth of the liraglutide market in the upcoming years. Diabetes, a chronic condition characterized by the body’s inability to effectively regulate blood sugar levels, is on the rise due to sedentary lifestyles, unhealthy diets, and increasing obesity rates globally. Liraglutide, a diabetes medication, mimics the action of the hormone GLP-1, enhancing insulin secretion, lowering blood sugar levels, and promoting weight loss, thereby aiding in managing type 2 diabetes. For instance, in 2021, the International Diabetes Federation (IDF), a Belgium-based non-profit organization, reported that 537 million adults aged 20–79, or 1 in 10, were living with diabetes. This number is projected to rise to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes live in low- and middle-income countries. Consequently, the increasing diabetic population is driving the growth of the liraglutide market.

Get A Free Sample On The Liraglutide Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

What Are The Key Trends That Influence Liraglutide Market Share Analysis?
Major companies in the liraglutide market are developing novel products like generic GLP-1 to broaden treatment options and meet the growing demand for more affordable alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists produced after the original branded medications’ patent protection expires, offering cost-effective treatments for conditions like type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched the first generic GLP-1 similar to Victoza in the U.S. market, addressing the increasing demand for these therapies. Liraglutide injections are prescribed to improve blood sugar management in adults and children aged 10 and above with type 2 diabetes and to lower the risk of cardiovascular incidents in adults with type 2 diabetes and existing cardiovascular conditions.

Which Market Players Are Driving Growth In The Liraglutide Market?
Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

How Is The Global Liraglutide Market Segmented?
The liraglutide market covered in this report is segmented –
1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings

Read The Full Liraglutide Market Report Here
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

The Liraglutide Global Market Report 2024 provides an overview of the liraglutidemarket for the time series: historic years (2010 – 2021) and ten years forecast (2023 – 2032). The liraglutide market forecast analyzes liraglutide market size, liraglutide market share, leading competitor and their market positions.

The Table Of Content For The Liraglutide Market Include
1. Liraglutide Market Executive Summary
2. Liraglutide Market Segments
3. Liraglutide Market Size And Template Market Growth Rate
4.  Key Liraglutide Market Trends
5. Major Liraglutide Market Drivers
……
25. Key Mergers And Acquisitions In The Liraglutide Market
26. Top Liraglutide Companies
27. Liraglutide Market Opportunities And Strategies
28. Liraglutide Market, Conclusions And Recommendations
29. Appendix

Explore Similar Reports From The Business Research Company:

Antidiarrheals Market 2024
https://www.thebusinessresearchcompany.com/report/antidiarrheals-global-market-report

Anti-Aging Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anti-aging-global-market-report

Television Network Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/television-network-global-market-report

Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: